A curcumin analogue GO‐Y030 depletes cancer stem cells by inhibiting the interaction between the HSP70/HSP40 complex and its substrates

Abstract

Cancer stem cells (CSCs) are proposed to be involved in tumor initiation and play important roles in cancer relapse, metastasis, and drug resistance. Therefore, the targeting of CSCs has potential for effective anticancer therapies. Curcumin is one of the most widely characterized phytochemicals with tumor‐suppressive potential. GO‐Y030 is a novel curcumin analogue exhibiting a much stronger growth‐inhibitory effect than curcumin. In the present study, we verified the potency of GO‐Y030 against a CSC population. We observed that GO‐Y030 suppressed CSC sphere‐forming ability in several cancer cell lines. Interestingly, a specific inhibitor of heat shock protein (HSP) 70 also exhibited effects similar to GO‐Y030 (i.e. inhibition of CSC sphere formation and upregulation of HSP70 and HSP40 protein expression), suggesting that HSP70 and/or HSP40 might be target molecules of GO‐Y030. We then performed an in vitro HSP70/HSP40‐mediated refolding activity assay and observed that chaperone activity was efficiently inhibited by GO‐Y030. Finally, we performed a substrate‐binding assay to show that GO‐Y030 reduced the binding of both HSP70 and HSP40 with their substrates. HSPs prevent denaturation or unfolding of client proteins under stressful conditions such as high temperature. Because CSCs by nature adapt to various stresses by reinforcing protein‐folding activity, the function of HSP70/HSP40 is important for the maintenance of CSC population. Our data suggest that GO‐Y030 may impair stress tolerance in CSCs by inhibiting the interaction of HSP70/HSP40 with their substrate proteins and disrupting the function of HSP70/HSP40, thereby contributing to a reduction of the CSC population.

Curcuminoids as Anticancer Drugs: Pleiotropic Effects, Potential for Metabolic Reprogramming and Prospects for the Future

“…The way curcumin analogs boost the efficacy of anti-immune checkpoint inhibitors also represents a new research field under development [ 30 ]. Finally, among the 25 recently reviewed curcumin analogs [ 15 ], at least eight have been the subject of continuous investigations with respect to their pleiotropic anticancer effects, in 2023 alone [ 254 , 255 , 256 , 257 , 258 , 259 , 260 , 261 ]. As these molecules may overcome limitations of bioavailability and pharmacokinetics that were recently reviewed based on clinical data [ 17 ], the hope is that the current research might soon lead to clinical trials involving cancer patients for at least some of them.…”

The dual face of microglia (M1/M2) as a potential target in the protective effect of nutraceuticals against neurodegenerative diseases

“…In addition, curcumin inhibits apoptosis, PI3k/Akt and iNOS, lipoxygenase, and COX-2, and induces activation of HO-1, Nrf-2, and the antioxidant response element mechanism in neuronal cells as well as microglia ( Ghasemi et al, 2019 ). Furthermore, curcumin also rescues downregulated molecular chaperones in HD, including Hsp40 and Hsp70, which have superior roles in the disease progression ( Suzuki et al, 2023 ).…”

Curcumin: a natural organic component that plays a multi-faceted role in ovarian cancer

“…Curcumin also has the ability to weaken the adhesion and invasion of EOC spheres to the extracellular matrix and mesothelial monolayer, thereby inhibiting metastasis [ 122 ]. A curcumin analogue GO-Y030 depletes cancer stem cells by inhibiting the interaction between the HSP70/HSP40 complex and its substrates [ 123 ].…”